Merck CEO Rob Davis announced that the company is transforming its portfolio beyond its reliance on the cancer drug Keytruda. He stated that Merck now has seven therapeutic areas and plans to launch over 20 new products in the next five years, potentially generating $70 billion in revenue by the mid-2030s. Key developments include FDA approvals of new treatments like Winrevair for rare lung disease and Lipfendra for cholesterol management, alongside the introduction of a faster-acting injectable Keytruda. Despite Merck’s strong recent performance, including a revenue outlook increase, the company has lowered its profit guidance due to acquisition-related charges. Shares have risen about 60% over the past year, outperforming the broader pharmaceutical sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.cnbc.com/2026/08/04/merck-ceo-pipeline-built-offset-keytruda-patent-expiration.html
